News Column

Covance Reports First Quarter Net Revenue Growth Of 6.9% To $620 Million, Pro Forma EPS Growth Of 20.1% To $0.90 And Adjusted Net Orders Of $710...

May 17, 2014



Covance Reports First Quarter Net Revenue Growth Of 6.9% To $620 Million, Pro Forma EPS Growth Of 20.1% To $0.90 And Adjusted Net Orders Of $710 Million

By a News Reporter-Staff News Editor at Investment Weekly News -- Covance Inc. (NYSE: CVD) reported results for its first quarter ended March 31, 2014. Net revenue was $620 million, representing 6.9% growth from the first quarter of 2013. On a GAAP basis, the company reported earnings of $0.88 per diluted share in the first quarter. Excluding a gain on the sale of our Seattle genomics laboratory of $1.6 million and charges associated with restructuring and other cost reduction actions totaling $4.1 million, the company reported earnings per diluted share of $0.90, up 20.1% over the first quarter of 2013.

"Covance's first quarter of 2014 featured a higher level of new toxicology orders and continued operational success in our clinical and central laboratory service offerings. Our 20% year-on-year increase in pro forma EPS was driven by 7% revenue growth and expanded pro forma operating margins of 11.5%," said Joe Herring, Chairman and Chief Executive Officer. "Adjusted net orders in the first quarter were $710 million, representing an adjusted net book-to-bill of 1.15 to 1. Net orders remained strong in central laboratories and grew significantly in toxicology and clinical pharmacology, offsetting lower-than-expected net orders in clinical development.

"Late-Stage Development first quarter revenues grew 7.8% year-on-year to $402 million. Central laboratories and clinical development grew 11% and 6%, respectively, which more than offset a decline in our market access services. Late-Stage Development operating margin expanded to 23.2%.

"Early Development results were in-line with our expectation with revenue increasing 5.3% year-on-year to $218 million with pro forma operating margin of 9.7%. Sequentially, growth in clinical pharmacology, research products, and nutritional chemistry was more than offset by the sale of our Seattle genomics laboratory and seasonal declines in toxicology and discovery support. Early Development second quarter revenue and operating margin are expected to increase considerably from the seasonally weak first quarter level.

"Looking ahead, we expect increases of a few cents in earnings per share each quarter as we progress throughout the year. We are narrowing our 2014 financial expectations to revenue growth of 6% to 9% and pro forma diluted earnings per share of $3.70 to $3.95 (excluding the gain on sale, costs associated with our on-going restructuring activities and assuming foreign exchange rates remain at March 31, 2014 levels)."

Keywords for this news article include: Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Investment Weekly News


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters